2025 Schedule

November 13 – 14, 2025 • Ritz-Carlton Laguna Niguel,

Dana Point, CA

Schedule

PART I

Moving Personalized Medicine Forward: Advancements and Directions for the Future

7:30 a.m.
Registration and Breakfast
8:30 a.m.
Opening Remarks

SPEAKER | Daryl Pritchard, Ph.D., President, Personalized Medicine Coalition

8:45 a.m.
The Past, Present, and Future of Innovation in Personalized Medicine: A Fireside Chat with Peter Marks, M.D., Ph.D.

MODERATOR | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus

KEYNOTE SPEAKER | Peter Marks, M.D., Ph.D., Senior Vice President & Head, Infectious Diseases & Molecule Discovery, Eli Lilly; Former Director, Center for Biologics Evaluation & Research, U.S. Food & Drug Administration; Independent Pharmaceutical Consultant

9:15 a.m.
Beyond Gene Testing: Next Generation Personalized Medicine Diagnostic Technologies in Clinical Practice (Proteomics, Metagenomics, ctDNA, and Digital Tools)

This session explores the cutting edge of personalized medicine beyond traditional gene testing, highlighting the clinical integration of next-generation diagnostic technologies. Experts will discuss the promise and practical application of proteomics, metagenomics, circulating tumor DNA (ctDNA), and digital diagnostic tools in delivering more precise, timely, and individualized care.

MODERATOR | Yuri Fesko, M.D., Senior Vice President & Chief Medical Officer, Quest Diagnostics

PANELIST | Esther Abels, Founder & Chief Executive Officer, SolarisRTC

PANELIST | Lourdes Barrera, Executive Director, Global Medical Affairs Oncology, Precision Medicine, Merck

PANELIST | David Kurtz, M.D., Ph.D., Co-Founder, Chief Medical Officer, Head of Research, Foresight Diagnostics

PANELIST | Ofer Sharon, M.D., Chief Executive Officer, OncoHost

10:00 a.m.
Networking Break

Sponsored by:

10:30 a.m.
Evolving Clinical Practice Trends for the Implementation of Precision Oncology

This session will present updated findings from the groundbreaking research study analyzing clinical practice gaps in the implementation of personalized medicine for advanced non–small cell lung cancer (aNSCLC). Building on a previously published seven-step clinical practice gap framework, which identified key barriers to optimal use of biomarker-directed therapies, this new analysis uses more recent data to assess progress over the past four years. Attendees will gain insights into evolving clinical practice trends and ongoing challenges in delivering precision oncology.

PRESENTER | Susanne Munksted, Chief Precision Medicine Officer, Diaceutics

10:45 a.m.
The Business of Personalized Medicine: Developing Viable Commercial Strategies for Personalized Medicine Companies

Industry innovation in diagnostic technologies and targeted treatment strategies drives progress in personalized medicine. But the path to market is fraught with obstacles. Pioneering investors and executives reflect on how to deal with challenges and uncertainty in an increasingly variable development and market environment.

MODERATOR | Kristin Ciriello Pothier, Life Sciences Sector Leader, Global Deal Advisory & Strategy Leader, Healthcare & Life Sciences, KPMG LLP

PANELIST | Namandje Bumpus, Ph.D., Strategic Advisor, Healthcare Policies and Scientific Strategy, Avalere Health; Former Principal Deputy Commissioner, U.S. Food and Drug Administration

PANELIST | Andy Moye, Ph.D., Senior Vice President & General Manager of Data Products, Tempus

PANELIST | Michael J. Pellini, M.D., Managing Partner, Section 32

11:30 a.m.
Blood-Based Diagnostic Strategies: Business and Clinical Approaches for the Future of Precision Oncology

MODERATOR | Clifton Leaf, Visiting Member, Ellison Medical Institute; former Editor-in-Chief, FORTUNE Magazine

KEYNOTE SPEAKER | Helmy Eltoukhy, Ph.D., Co-Chief Executive Officer & Chairman of the Board, Guardant Health

KEYNOTE SPEAKER | AmirAli Talasaz, Ph.D., Co-Chief Executive Officer & Director, Guardant Health

12:00 p.m.
Lunch Break and Sponsored Lunch Breakout Sessions
1:00 p.m.
The Future of Cancer If We Deliver on the Promise of Emerging Early Detection Technologies

By detecting molecular cancer signals in blood samples of seemingly healthy patients, a new generation of early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner, when cancer may be more effectively treated. What might this mean for the future of cancer care? Leading voices discuss.

MODERATOR | Omar Perez, Ph.D., U.S. Head of Medical Diagnostics, AstraZeneca

PANELIST | Tomasz Beer, M.D., Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

PANELIST | Ora K. Gordon, M.D., Clinical Director, Population Genomics Program, Providence Health

PANELIST | Eric Klein, M.D., Distinguished Scientist, GRAIL

PANELIST | Dawn Mattoon, Ph.D., Chief Executive Officer, Mercy BioAnaytics, Inc.

1:45 p.m.
Personalized Medicine and the Pharmaceutical Industry: A Keynote Interview

MODERATOR | Clifton Leaf, Visiting Member, Ellison Medical Institute; former Editor-in-Chief, FORTUNE Magazine

KEYNOTE SPEAKER | Anthony Sireci, Senior Vice President, Clinical Biomarkers, Laboratories & Diagnostics, Eli Lilly

2:15 p.m.
Artificial Intelligence-Driven Platforms Accelerating Biomarker and Treatment Development

Machine learning and artificial intelligence technologies can drive biomarker discovery and validation and more readily explore divergent effects of preventive and treatment interventions across extensive data sets. What might this mean for the future of personalized medicine and what is being done to realize that future?

MODERATOR | Douglas Clark, M.D., Chief Pathologist, Life Sciences & Diagnostics Markets Group, Agilent Technologies

PANELIST | Ángel Alberich-Bayarri, Ph.D., Founder & Chief Executive Officer, Quibim

PANELIST | Laura Carter, Ph.D., Chief Scientific Officer, Character Biosciences

PANELIST | Yaik Ho, Ph.D., Head of Strategy, Oncology Data Science & AI, AstraZeneca

PANELIST | Michael Montalto, Ph.D., Vice President, Precision Medicine Global Development, Amgen

3:00 p.m.
Networking Break

Sponsored by:

3:30 p.m.
Presentation of the 20th Annual Award for Leadership in Personalized Medicine

PRESENTER | Mara Aspinall, Professor of Practice, College of Health Solutions, Arizona State University

AWARDEE | George Poste, D.V.M., Ph.D., Regents’ Professor and Del E. Webb Chair in Health Innovation; Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University

4:00 p.m.
Emerging Personalized Medicine Disciplines: Biomarker-Driven Treatment Strategies in Cardiovascular, Neurodegenerative, Kidney, and Infectious Diseases

MODERATOR | Dan Roden, M.D., Professor of Medicine, Pharmacology, & Biomedical Informatics; Senior Vice President, Personalized Medicine, Vanderbilt University Medical Center

PANELIST | Doug Biehn, President & Chief Executive Officer, Octave Bioscience, Inc.

PANELIST | Edward Hickey, President & Chair, American Association of Kidney Patients (AAKP) Veterans Health Initiative, U.S.M.C.

PANELIST | Damon Hostin, Global Lead, Market Access, Illumina

PANELIST | Brad Perkins, M.D., Chief Medical Officer, Karius, Inc.

4:45 p.m.
Engaging with the Global Community is More Important than Ever: International Efforts in Personalized Medicine and Advanced Technologies

Engaging with the global community is now more vital than ever for advancing personalized medicine, especially when considering shared knowledge, coordinated policy development, and international clinical adoption strategies. With rapid innovations in advanced technologies—including cell-based and gene therapies—new models of care are emerging, such as regional clinical delivery hubs in Europe designed to streamline patient access and accelerate implementation. Speakers will discuss efforts to harmonize regulatory frameworks and other innovative approaches to ensure equitable, timely delivery of transformative therapies worldwide.

MODERATOR | David Morrow, Ph.D., Scientific Lead for Advanced Therapies, European Infrastructure for Translational Medicine (EATRIS)

PANELIST | Gabriele Allegri, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

PANELIST | Brian Heath, Senior Vice President & Global Head, Commercial, Kite Pharma

PANELIST | Ayah Ziyada, M.Sc. Ph.D. Candidate, Precision Medicine Program Manager, Center for Clinical Precision Medicine and Genomics, Hamad Medical Corporation, Qatar

 

5:30 p.m.
Welcome Reception

PART II

Implementing Personalized Medicine in a New Era

7:30 a.m.
Registration and Breakfast
8:30 a.m.
Opening Remarks

SPEAKER | Lincoln Nadauld, M.D., Ph.D., President & Chief Executive Officer, Culmination Bio

8:45 a.m.
Policies and Platforms for the Data Analysis Revolution: Reflections on Harnessing Data Technologies to Advance Precision Health

As advanced data technologies redefine personalized medicine, strategic development and sound policy are essential to realizing their full potential. In this keynote, Stacy Cline Amin, Vice President and Chief Counsel for Global Health Regulatory and Policy at Oracle, will share her perspective on how regulatory innovation, data accessibility, and cross-sector partnerships can shape the future of precision health in the era of advanced analytics and digital transformation.

INTRODUCTION | Cynthia Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

KEYNOTE SPEAKER | Stacy Cline Amin, Vice President, Chief Counsel for Global Health Regulatory and Policy, Oracle

9:15 a.m.
Artificial Intelligence for Biomarker-Driven Clinical Decision Support and Implementation of Personalized Medicine

MODERATOR | Okan Ekinci, M.D., Chief Medical Information Officer & Global Head of Digital Technology, Roche Information Solutions, Roche Diagnostics

PANELIST | Thomas Brown, M.D., Chief Medical Officer, Sygnomics

PANELIST | Aradhana Ghosh, M.D., Vice President, RWD Product Development, Labcorp

PANELIST | Apostolia Tsimberidou, M.D., Ph.D., Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

PANELIST | Alex Vadas, Ph.D., Managing Director, LEK Consulting

 

10:00 a.m.
Networking Break

Sponsored by:

10:30 a.m.
What Is Needed to Improve the Delivery of Personalized Medicine? A Strategic Roadmap for Implementing Precision Oncology

Our scientific understanding and technological development for personalized medicine is way ahead of the policies and practices needed to fully realize the field’s value. Clinical implementation of personalized medicine technologies is fraught with challenges. A community approach to developing and implementing strategies to more consistently and effectively deliver personalized medicine is gaining traction. But, much is still needed to be done. What is needed to improve access and implementation?

MODERATOR | Burns Blaxall, Ph.D., Principal Consultant, PMG Insights

PANELIST | Suzzette Arnal, Ph.D., Vice President, Precision Medicine, Oncology & Multispecialty, McKesson

PANELIST | Jonathan Katchmore, Associate Vice President, Commercial Diagnostic Strategy, Eli Lilly and Company

PANELIST | Rob Monroe, M.D. Ph.D., Chief Scientific Officer, Oncology, Danaher Diagnostics; Chief Medical Officer, Leica Biosystem

PANELIST | Prajit Pillai, Ph.D., Co-Founder, Head of Business Strategy & Technology Development, Precision Medicine Diagnostic Partners

11:15 a.m.
Recognizing the Clinical Utility of Personalized Medicine: Market Access Perspectives Related to Value, Coverage, and Reimbursement

Evidence of clinical utility is central to how payers and providers assess value, set coverage policies, and determine reimbursement for personalized medicine technologies. Experts will discuss the evidentiary standards necessary for bringing personalized medicine technologies to market, and strategies to ensure patients have timely access to innovative biomarker-driven diagnostics and therapies.

MODERATOR | Suzanne Belinson, Ph.D., Vice President, Commercial Markets, Tempus AI, Inc.

PANELIST | Lon Castle, M.D., Chief Medical Officer, Precision Medicine, EviCore healthcare

PANELIST | Cate Lockhart, Pharm.D., Ph.D., Chief Science Officer, Academy of Managed Care Pharmacy

PANELIST | Kathryn Phillips, Ph.D., Founding Director, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco

12:00 p.m.
Closing Remarks

SPEAKER | J. Brian Munroe, Vice President, Government Affairs, Bausch Health Companies Inc.

12:05 p.m.
Lunch Buffet